PE20060652A1 - Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion - Google Patents
Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusionInfo
- Publication number
- PE20060652A1 PE20060652A1 PE2005000979A PE2005000979A PE20060652A1 PE 20060652 A1 PE20060652 A1 PE 20060652A1 PE 2005000979 A PE2005000979 A PE 2005000979A PE 2005000979 A PE2005000979 A PE 2005000979A PE 20060652 A1 PE20060652 A1 PE 20060652A1
- Authority
- PE
- Peru
- Prior art keywords
- granules
- compound
- fusion
- immediate release
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE ADMINISTRACION ORAL DE LIBERACION INMEDIATA, QUE INCLUYE GRANULOS DE FUSION QUE COMPRENDE i) UN COMPUESTO TERAPEUTICO SENSIBLE A LA HUMEDAD, TAL COMO UN INHIBIDOR DE DIPEPTIDILPEPTIDASAS IV (DPP-IV), SIENDO SELECCIONADA (S)-1-[(3-HIDROXI-1-ADAMANTIL)AMINO]ACETIL-2-CIANO-PIRROLIDINA; Y ii) UN COMPONENETE DE FUSION HIDROFOBICO TAL COMO ESTERES, CERAS, HIDROCARBUROS, ALCOHOLES GRASOS, ACIDOS GRASOS, TRIGLICERIDOS, ENTRE OTROS O MEZCLAS DE ESTOS; AMBOS COMPUESTOS ESTAN PRESENTES EN UN RANGO DE 1:1 A 1:10. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION DE ESTOS GRANULOS DE FUSION QUE INCLUYE a) FORMAR UNA MEZCLA DEL COMPUESTOS i) CON AL MENOS UN COMPUESTO DE ii); b) CALENTAR DICHA MEZCLA A UNA TEMPERATURA APROXIMADA, O EN EL RANGO DE FUSION DEL COMPONENTE DE FUSION HIDROFOBICO; c) GRANULAR LA MEZCLA BAJO ALTO ESFUERZO CORTANTE; Y d) ENFRIAR LOS GRANULOS A TEMPERATURA AMBIENTE. EN ESTOS GRANULOS EL COMPUESTO SENSIBLE A LA HUMEDAD ES CUBIERTO O SUBSTANCIALMENTE CUBIERTO POR EL COMPUESTO DE FUSION HIDROFOBICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60532704P | 2004-08-27 | 2004-08-27 | |
| US61682804P | 2004-10-07 | 2004-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060652A1 true PE20060652A1 (es) | 2006-08-11 |
Family
ID=35447883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000979A PE20060652A1 (es) | 2004-08-27 | 2005-08-25 | Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20080050443A1 (es) |
| EP (2) | EP1786401B1 (es) |
| JP (1) | JP5147399B2 (es) |
| KR (8) | KR20160136465A (es) |
| CN (1) | CN101010068B (es) |
| AR (1) | AR050615A1 (es) |
| AU (1) | AU2005276583B2 (es) |
| BR (1) | BRPI0514682B8 (es) |
| CA (1) | CA2575499A1 (es) |
| DK (1) | DK1786401T3 (es) |
| ES (1) | ES2647671T3 (es) |
| HU (1) | HUE034653T2 (es) |
| MX (1) | MX2007002253A (es) |
| MY (1) | MY144297A (es) |
| PE (1) | PE20060652A1 (es) |
| PL (1) | PL1786401T3 (es) |
| PT (1) | PT1786401T (es) |
| RU (1) | RU2383332C2 (es) |
| SI (1) | SI1786401T1 (es) |
| TW (1) | TWI402082B (es) |
| WO (1) | WO2006021455A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080038341A1 (en) | 2004-01-20 | 2008-02-14 | James Kowalski | Direct Compression Formulation And Process |
| ES2375625T3 (es) * | 2004-02-05 | 2012-03-02 | Kyorin Pharmaceutical Co., Ltd. | Derivados de biciclo éster. |
| AR050615A1 (es) | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| CN101395131B (zh) | 2006-03-08 | 2012-11-14 | 杏林制药株式会社 | 氨基乙酰基吡咯烷甲腈衍生物的制备方法及其制备中间体 |
| WO2007128801A1 (en) * | 2006-05-08 | 2007-11-15 | Novartis Ag | Combination of organic compounds |
| ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
| DE102008020701A1 (de) * | 2008-04-24 | 2009-10-29 | Bayer Technology Services Gmbh | Formulierung mit reduzierter Hygroskopizität |
| WO2010016584A1 (ja) | 2008-08-07 | 2010-02-11 | 杏林製薬株式会社 | ビシクロ[２．２．２]オクチルアミン誘導体の製造方法 |
| EP2327406A4 (en) * | 2008-08-14 | 2014-04-09 | Kyorin Seiyaku Kk | STABILIZED PHARMACEUTICAL COMPOSITION |
| AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2010110436A1 (ja) | 2009-03-27 | 2010-09-30 | 杏林製薬株式会社 | 塩基性添加剤を含有するマトリックス型徐放性製剤 |
| JP2011057586A (ja) * | 2009-09-08 | 2011-03-24 | Kyorin Pharmaceutical Co Ltd | ｐＨ非依存性マトリックス型徐放性製剤 |
| TR201002256A1 (tr) * | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
| US9071358B2 (en) | 2012-06-21 | 2015-06-30 | Qualcomm Incrorporated | Repeater fiber-coax units |
| US8989577B2 (en) | 2012-06-21 | 2015-03-24 | Qualcomm Incorporated | Methods and systems for implementing time-division duplexing in the physical layer |
| US9363017B2 (en) | 2012-07-06 | 2016-06-07 | Qualcomm Incorporated | Methods and systems of specifying coaxial resource allocation across a MAC/PHY interface |
| WO2014065427A1 (ja) * | 2012-10-26 | 2014-05-01 | 株式会社 三和化学研究所 | アナグリプチン含有固形製剤 |
| US10369108B2 (en) * | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| CN104274408A (zh) * | 2013-07-10 | 2015-01-14 | 北京科信必成医药科技发展有限公司 | 一种熔融包衣的速释药物微粒及其制备方法 |
| WO2015195990A1 (en) * | 2014-06-20 | 2015-12-23 | Banner Life Sciences Llc | Liquid-filled immediate release soft gelatin capsules |
| EP3512505B1 (en) | 2016-09-16 | 2023-03-15 | Galenicum Health S.L.U. | Vildagliptin pharmaceutical compositions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109770A0 (en) | 1993-05-29 | 1994-11-28 | Smithkline Beecham Corp | Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby |
| WO1995005808A1 (en) * | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
| EP0654263B1 (en) * | 1993-11-23 | 2002-01-23 | Euro-Celtique S.A. | Method for preparing a sustained release composition |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US20020142037A1 (en) * | 1996-10-01 | 2002-10-03 | Nabil Farah | Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix |
| AU4721897A (en) | 1996-10-25 | 1998-05-22 | Tanabe Seiyaku Co., Ltd. | Tetrahydroisoquinoline derivatives |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6692767B2 (en) | 1997-09-19 | 2004-02-17 | Shire Laboratories Inc. | Solid solution beadlet |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
| IL157179A0 (en) | 2001-02-02 | 2004-02-08 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| EP1537880A4 (en) * | 2002-09-11 | 2009-07-01 | Takeda Pharmaceutical | Sustained release preparation |
| NZ538897A (en) | 2002-10-18 | 2007-02-23 | Merck & Co Inc | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004037181A2 (en) | 2002-10-23 | 2004-05-06 | Bristol-Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| AR050615A1 (es) | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
-
2005
- 2005-08-25 AR ARP050103558A patent/AR050615A1/es not_active Application Discontinuation
- 2005-08-25 PE PE2005000979A patent/PE20060652A1/es not_active Application Discontinuation
- 2005-08-26 SI SI200532179T patent/SI1786401T1/sl unknown
- 2005-08-26 EP EP05775067.1A patent/EP1786401B1/en active Active
- 2005-08-26 HU HUE05775067A patent/HUE034653T2/hu unknown
- 2005-08-26 JP JP2007528755A patent/JP5147399B2/ja active Active
- 2005-08-26 RU RU2007110953/15A patent/RU2383332C2/ru active
- 2005-08-26 PT PT57750671T patent/PT1786401T/pt unknown
- 2005-08-26 KR KR1020167032323A patent/KR20160136465A/ko active Search and Examination
- 2005-08-26 CA CA002575499A patent/CA2575499A1/en not_active Abandoned
- 2005-08-26 MX MX2007002253A patent/MX2007002253A/es active IP Right Grant
- 2005-08-26 KR KR1020177024422A patent/KR20170103039A/ko not_active Application Discontinuation
- 2005-08-26 KR KR1020227013566A patent/KR20220061249A/ko active Application Filing
- 2005-08-26 KR KR1020137009959A patent/KR101613775B1/ko active IP Right Grant
- 2005-08-26 BR BRPI0514682A patent/BRPI0514682B8/pt active IP Right Grant
- 2005-08-26 MY MYPI20054015A patent/MY144297A/en unknown
- 2005-08-26 KR KR1020207019819A patent/KR20200087870A/ko not_active Application Discontinuation
- 2005-08-26 PL PL05775067T patent/PL1786401T3/pl unknown
- 2005-08-26 KR KR1020077004461A patent/KR20070049646A/ko active Search and Examination
- 2005-08-26 KR KR1020197001094A patent/KR20190006612A/ko not_active Application Discontinuation
- 2005-08-26 ES ES05775067.1T patent/ES2647671T3/es active Active
- 2005-08-26 WO PCT/EP2005/009252 patent/WO2006021455A1/en active Application Filing
- 2005-08-26 EP EP16169370.0A patent/EP3087975A1/en not_active Ceased
- 2005-08-26 CN CN2005800289311A patent/CN101010068B/zh not_active Expired - Fee Related
- 2005-08-26 AU AU2005276583A patent/AU2005276583B2/en not_active Ceased
- 2005-08-26 TW TW094129377A patent/TWI402082B/zh not_active IP Right Cessation
- 2005-08-26 US US11/573,658 patent/US20080050443A1/en not_active Abandoned
- 2005-08-26 DK DK05775067.1T patent/DK1786401T3/da active
- 2005-08-26 KR KR1020167002363A patent/KR20160017123A/ko not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060652A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion | |
| US6407101B1 (en) | Cyanopyrroles | |
| PE20050686A1 (es) | Formulacion para compresion directa y proceso | |
| MX2009003727A (es) | Acidos y esteres boronicos como inhibidores de amida hidrolasa de acido graso. | |
| CL2007003821A1 (es) | Compuestos derivados de isoquinolina o isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades asociadas con la rho-quinasa y/o la fosforilacion mediada por la rho-quinasa de la cadena ligera de miosina, tales como hipertension, retinopatia, glaucoma, alzheimer, sida entre otras. | |
| AR034124A1 (es) | Forma cristalina alfa de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| CN103946226A (zh) | 杂环化合物及其应用 | |
| PE20061091A1 (es) | FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN | |
| ECSP003713A (es) | Derivados de purina | |
| ECSP003712A (es) | Derivados de la purina | |
| PE20080331A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
| PE20040450A1 (es) | Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| RU2012116335A (ru) | Таблетки, преобразуемые в ротовой полости | |
| BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
| PE20070179A1 (es) | Derivados de purina como agonistas del receptor de adenosina a2 | |
| NI200800024A (es) | Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa | |
| BRPI0510909A2 (pt) | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor | |
| BR0309004A (pt) | Matriz para liberação gradual, invariante e independente dos compostos ativos | |
| HN1999000106A (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. | |
| GT200100187A (es) | Derivados de purina | |
| CR9219A (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| BR9912073A (pt) | Composições farmacêuticas que compreendem 2-quinolonas | |
| PE20110206A1 (es) | Derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ES2207334T3 (es) | Composicion farmaceutica de liberacion controlada, con mesilato de tilidina como principio activo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |